COMP <GO>
OCS vs INDP // EV/EBITDA & P/E VALUATION
Oculis Holding AG (NASDAQ) VS. Indaptus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OCS 0
— INDP 2
■ METRIC PARITY
LAST: $8.24 (+3.26%) • MKT CAP: $507.5M
valuation
—
LAST: $3.34 (+0.30%) • MKT CAP: $513.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCS VS. INDP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCS | INDP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.89% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.6 | 54.2 | -8.57 | INDP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $507.5M | $513.0M | -$5.5M | INDP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCS REV | INDP REV | OCS GROSS % | INDP GROSS % | OCS FCF | INDP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$14.8M |
| FY 2024 | — | $0 | — | — | — | -$12.3M |
| FY 2023 | — | $0 | — | — | — | -$13.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCS // BETA —
INDP // BETA —